HRP20241552T1 - Acetil-leucin ili njegova farmaceutski prihvatljiva sol za poboljšanu pokretljivost - Google Patents

Acetil-leucin ili njegova farmaceutski prihvatljiva sol za poboljšanu pokretljivost Download PDF

Info

Publication number
HRP20241552T1
HRP20241552T1 HRP20241552TT HRP20241552T HRP20241552T1 HR P20241552 T1 HRP20241552 T1 HR P20241552T1 HR P20241552T T HRP20241552T T HR P20241552TT HR P20241552 T HRP20241552 T HR P20241552T HR P20241552 T1 HRP20241552 T1 HR P20241552T1
Authority
HR
Croatia
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
dose
Prior art date
Application number
HRP20241552TT
Other languages
English (en)
Croatian (hr)
Inventor
Mallory Factor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of HRP20241552T1 publication Critical patent/HRP20241552T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20241552TT 2016-04-19 2017-04-19 Acetil-leucin ili njegova farmaceutski prihvatljiva sol za poboljšanu pokretljivost HRP20241552T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
EP17719692.0A EP3445351B1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility

Publications (1)

Publication Number Publication Date
HRP20241552T1 true HRP20241552T1 (hr) 2025-01-17

Family

ID=58633040

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241552TT HRP20241552T1 (hr) 2016-04-19 2017-04-19 Acetil-leucin ili njegova farmaceutski prihvatljiva sol za poboljšanu pokretljivost

Country Status (26)

Country Link
US (4) US10905670B2 (https=)
EP (2) EP4501406A3 (https=)
JP (3) JP7387264B2 (https=)
KR (4) KR102791288B1 (https=)
CN (2) CN109069463B (https=)
AU (2) AU2017252507B2 (https=)
BR (1) BR112018071547A2 (https=)
CA (1) CA3021155A1 (https=)
DK (1) DK3445351T3 (https=)
ES (1) ES2994242T3 (https=)
FI (1) FI3445351T3 (https=)
HR (1) HRP20241552T1 (https=)
HU (1) HUE069219T2 (https=)
IL (3) IL310508A (https=)
LT (1) LT3445351T (https=)
MD (1) MD3445351T2 (https=)
MX (2) MX388461B (https=)
PL (1) PL3445351T3 (https=)
PT (1) PT3445351T (https=)
RS (1) RS66142B1 (https=)
RU (1) RU2745912C2 (https=)
SG (2) SG10202106190RA (https=)
SI (1) SI3445351T1 (https=)
SM (1) SMT202400459T1 (https=)
WO (1) WO2017182802A1 (https=)
ZA (1) ZA201806849B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905670B2 (en) * 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル-ロイシンの重水素化類似体
WO2020178721A1 (en) * 2019-03-02 2020-09-10 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease
US20250099355A1 (en) 2023-07-18 2025-03-27 Sytheon Ltd Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
CA2687107A1 (en) * 2007-05-08 2008-11-13 Northern Innovations And Formulations Corp. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
US20120196257A1 (en) * 2009-08-27 2012-08-02 Joe Verghese Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
US10905670B2 (en) * 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
US12458614B2 (en) * 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders

Also Published As

Publication number Publication date
EP4501406A2 (en) 2025-02-05
IL293266B2 (en) 2024-07-01
KR20240018683A (ko) 2024-02-13
IL293266A (en) 2022-07-01
DK3445351T3 (da) 2024-11-04
AU2017252507B2 (en) 2022-07-21
BR112018071547A2 (pt) 2019-03-06
KR20220093386A (ko) 2022-07-05
SI3445351T1 (sl) 2025-04-30
CA3021155A1 (en) 2017-10-26
RU2745912C2 (ru) 2021-04-02
RU2018140131A3 (https=) 2020-05-14
LT3445351T (lt) 2024-11-25
IL262379B (en) 2022-07-01
SMT202400459T1 (it) 2025-01-14
ES2994242T3 (en) 2025-02-05
US20210106548A1 (en) 2021-04-15
CN109069463B (zh) 2024-07-23
KR102791288B1 (ko) 2025-04-03
US20190083438A1 (en) 2019-03-21
US10905670B2 (en) 2021-02-02
MX2018012739A (es) 2019-06-17
US20230346732A1 (en) 2023-11-02
EP3445351B1 (en) 2024-10-16
RU2021107001A (ru) 2021-04-12
PT3445351T (pt) 2024-11-14
US20250332133A1 (en) 2025-10-30
CN118593463A (zh) 2024-09-06
AU2022256077A1 (en) 2022-11-17
KR102413754B1 (ko) 2022-06-27
JP2022024058A (ja) 2022-02-08
IL310508A (en) 2024-03-01
US11998518B2 (en) 2024-06-04
IL293266B1 (en) 2024-03-01
ZA201806849B (en) 2019-07-31
NZ747307A (en) 2025-10-31
JP7387264B2 (ja) 2023-11-28
RS66142B1 (sr) 2024-12-31
JP2024123087A (ja) 2024-09-10
KR20220038814A (ko) 2022-03-29
EP3445351A1 (en) 2019-02-27
RU2018140131A (ru) 2020-05-14
MX2021014844A (es) 2022-01-18
US12329733B2 (en) 2025-06-17
WO2017182802A1 (en) 2017-10-26
KR20180134398A (ko) 2018-12-18
JP2019513814A (ja) 2019-05-30
JP7506046B2 (ja) 2024-06-25
EP4501406A3 (en) 2025-03-26
KR102632670B1 (ko) 2024-02-01
HUE069219T2 (hu) 2025-02-28
SG11201809031XA (en) 2018-11-29
CN109069463A (zh) 2018-12-21
IL262379A (en) 2018-11-29
MD3445351T2 (ro) 2024-12-31
SG10202106190RA (en) 2021-07-29
MX388461B (es) 2025-03-20
PL3445351T3 (pl) 2025-01-07
AU2017252507A1 (en) 2018-11-08
FI3445351T3 (fi) 2024-11-18

Similar Documents

Publication Publication Date Title
HRP20241552T1 (hr) Acetil-leucin ili njegova farmaceutski prihvatljiva sol za poboljšanu pokretljivost
HRP20250250T1 (hr) Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji
HRP20250181T1 (hr) Spojevi i postupci za ciljanu razgradnju receptora androgena
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
IL245117B (en) Co-crystals of (n - (s-methyl-8-(1((2'-methyl-['4,5-bipyrimidine]-6-yl)amino)propane-2-yl)quinoline-4-carboxamide, Derivatives modified by their deuterium, methods for their preparation, preparations containing them and their uses
HRP20220759T1 (hr) Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
WO2014120808A8 (en) Pyridone amides as modulators of sodium channels
MX383665B (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
MX383706B (es) Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
WO2015044963A9 (en) An amorphous vortioxetine and salts thereof
HK1201828A1 (en) Treatment regimens using multiple pharmaceutical agents
ZA202105976B (en) Pharmaceutical dosage form for application to mucous membranes and methods for producing same
HRP20250899T1 (hr) Manitol za uporabu u liječenju hepatotoksičnosti i masnih bolesti jetre
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
MX2018005628A (es) Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
MY198553A (en) Pharmaceutical composition comprising metformin and lobeglitazone
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
HRP20191710T1 (hr) Postupci za liječenje poremećaja ciklusa uree
CN106456621A8 (zh) 用于治疗hcv的方法
MX381932B (es) Composicion intranasal que comprende betahistina.
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
SI2722322T1 (sl) 1,3-di-okso-indenski derivat, farmacevtsko sprejemljiva sol ali optični izomer le-tega, postopek njegov priprave in farmacevtski sestavek, ki ga vsebuje kot protivirusno aktivno sestavino
AR084195A1 (es) Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
IN2013MU03428A (https=)